Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in moderate to severe asthma
NCT05186909Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in asthma, sponsored by Keymed Biosciences. Started Jan 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05186909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186909.